explore
Previous article:
FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article: Senate panel puts off hardest PBM reforms for another day
Next article: Senate panel puts off hardest PBM reforms for another day
hotspot
hotspot
-
Maker of FluMist seeks to allow at
2025-09-27 12:54 -
Telehealth options flood the market as retailers push virtual care
2025-09-27 12:48 -
New lawsuit accuses health insurer Cigna of denying claims in bulk
2025-09-27 11:59 -
Readout Newsletter: The latest from Bristol, Sarepta, and Novartis
2025-09-27 11:23 -
Traditional Chinese medicine benefits explored in new JAMA study
2025-09-27 10:50 -
An exit interview with Bristol Myers Squibb CEO Giovanni Caforio
2025-09-27 10:48